146 related articles for article (PubMed ID: 37751309)
21. Recurrent RARG trinary fusion and ligand binding domain truncation in variant acute promyelocytic leukemia resistant to retinoic acid but sensitive to homoharringtonine-based therapy.
Chen X; Zhao Y; Zhou X; Chen J; Cao P; Wang F; Zhang Y; Wu P; Zhang L; Liu H
Int J Lab Hematol; 2023 Dec; 45(6):1016-1019. PubMed ID: 37605819
[No Abstract] [Full Text] [Related]
22. [Treatment for acute promyelocytic leukemia].
Fujita H
Rinsho Ketsueki; 2014 Oct; 55(10):1817-26. PubMed ID: 25297745
[No Abstract] [Full Text] [Related]
23. Recurrent
Osumi T; Tsujimoto SI; Tamura M; Uchiyama M; Nakabayashi K; Okamura K; Yoshida M; Tomizawa D; Watanabe A; Takahashi H; Hori T; Yamamoto S; Hamamoto K; Migita M; Ogata-Kawata H; Uchiyama T; Kizawa H; Ueno-Yokohata H; Shirai R; Seki M; Ohki K; Takita J; Inukai T; Ogawa S; Kitamura T; Matsumoto K; Hata K; Kiyokawa N; Goyama S; Kato M
Cancer Res; 2018 Aug; 78(16):4452-4458. PubMed ID: 29921692
[TBL] [Abstract][Full Text] [Related]
24. [M3, promyelocytic leukemia].
Tsuruoka N
Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):65-7. PubMed ID: 9851086
[No Abstract] [Full Text] [Related]
25. FISH-negative, cytogenetically cryptic acute promyelocytic leukemia.
Rashidi A; Fisher SI
Blood Cancer J; 2015 Jun; 5(6):e320. PubMed ID: 26090620
[No Abstract] [Full Text] [Related]
26. Clinical and genomic characterization of an ATRA-insensitive acute promyelocytic leukemia variant with a FNDC3B::RARB fusion.
Kirkham JK; Liu YC; Foy SG; Ma J; Gheorghe G; Furtado LV; Popescu MI; Klco JM; Karol SE; Blackburn PR
Genes Chromosomes Cancer; 2023 Oct; 62(10):617-623. PubMed ID: 37283355
[TBL] [Abstract][Full Text] [Related]
27. Retinoic acid and its rearranged receptor in the etiology and treatment of acute promyelocytic leukemia.
Frankel SR; Miller WH; Dmitrovsky E
Oncology (Williston Park); 1992 Aug; 6(8):74-78, 83; discussion 84, 87-8. PubMed ID: 1323988
[TBL] [Abstract][Full Text] [Related]
28. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.
Dong S; Tweardy DJ
Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748
[TBL] [Abstract][Full Text] [Related]
29. Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias.
Poplineau M; Platet N; Mazuel A; Hérault L; N'Guyen L; Koide S; Nakajima-Takagi Y; Kuribayashi W; Carbuccia N; Haboub L; Vernerey J; Oshima M; Birnbaum D; Iwama A; Duprez E
Blood; 2022 Dec; 140(22):2358-2370. PubMed ID: 35984905
[TBL] [Abstract][Full Text] [Related]
30. A case of acute promyelocytic leukaemia with unusual cytological features and a ZBTB16-RARA fusion gene.
Lechevalier N; Dulucq S; Bidet A
Br J Haematol; 2016 Aug; 174(4):502. PubMed ID: 27302179
[No Abstract] [Full Text] [Related]
31. Therapy-induced secondary acute myeloid leukemia with t(11;19)(q23;p13.1) in a pediatric patient with relapsed acute promyelocytic leukemia.
Dang DN; Morris HD; Feusner JH; Koduru P; Wilson K; Timmons CF; Cavalier M; Luu HS
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e546-8. PubMed ID: 24942021
[TBL] [Abstract][Full Text] [Related]
32. Pseudotumor cerebri in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid.
Sano F; Tsuji K; Kunika N; Takeuchi T; Oyama K; Hasegawa S; Koike M; Takahashi M; Ishida M
Intern Med; 1998 Jun; 37(6):546-9. PubMed ID: 9678691
[TBL] [Abstract][Full Text] [Related]
33. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.
Lehmann-Che J; Bally C; Letouzé E; Berthier C; Yuan H; Jollivet F; Ades L; Cassinat B; Hirsch P; Pigneux A; Mozziconacci MJ; Kogan S; Fenaux P; de Thé H
Nat Commun; 2018 May; 9(1):2047. PubMed ID: 29795382
[TBL] [Abstract][Full Text] [Related]
34. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment.
Park DJ; Chumakov AM; Vuong PT; Chih DY; Gombart AF; Miller WH; Koeffler HP
J Clin Invest; 1999 May; 103(10):1399-408. PubMed ID: 10330422
[TBL] [Abstract][Full Text] [Related]
35. [All-trans retinoic acid and arsenic trioxide: their molecular mechanisms of action and updated clinical progress in APL therapy].
Shinagawa K
Rinsho Ketsueki; 2011 Jul; 52(7):469-83. PubMed ID: 21821978
[No Abstract] [Full Text] [Related]
36. Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Ng Liet Hing M; Ryland GL; Nguyen T; Tiong IS; Dun K; Ninkovic S; Nedumannil R; Westerman DA; Blombery PA; Chan KL; Bajel A
Br J Haematol; 2023 Aug; 202(4):893-896. PubMed ID: 37280781
[No Abstract] [Full Text] [Related]
37. Acute promyelocytic leukemia: retinoic acid response and resistance.
Early E; Dmitrovsky E
J Investig Med; 1995 Aug; 43(4):337-44. PubMed ID: 7552583
[No Abstract] [Full Text] [Related]
38. Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells.
Zhang JW; Wang JY; Chen SJ; Chen Z
J Biosci; 2000 Sep; 25(3):275-84. PubMed ID: 11022230
[TBL] [Abstract][Full Text] [Related]
39. Molecular monitoring of minimal residual disease in acute promyelocytic leukemia by the polymerase chain reaction assay for the PML/RAR alpha (retinoic acid receptor-alpha) fusion transcript in patients treated with all-trans retinoic acid followed by chemotherapy.
Nemet D; Grahovac B; Labar B; Mrsić M; Radman I; Bogdanić V; Hitrec V; Zaher D; Aurer I; Sertić D
Haematologica; 1995; 80(3):238-40. PubMed ID: 7672716
[TBL] [Abstract][Full Text] [Related]
40. ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.
Tong Q; You H; Chen X; Wang K; Sun W; Pei Y; Zhao X; Yuan M; Zhu H; Luo Z; Zhang Y
Nucleic Acids Res; 2018 Apr; 46(7):3284-3297. PubMed ID: 29554366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
